
#### **OncoTargets and Therapy**

#### ORIGINAL RESEARCH

# Long Noncoding RNA *RGMB-AS1* Acts as a microRNA-574 Sponge Thereby Enhancing the Aggressiveness of Gastric Cancer via HDAC4 Upregulation

This article was published in the following Dove Press journal: OncoTargets and Therapy



**Methods:** RGMB-AS1 experimentation in GC as measured via reverse-transcription quantitative including Q l Counting Kit-8 assay, flow-cytometric analysis PCR. A series of experime of apoptosis, Trapswell migra, and jpc, sion assays, and in vivo tumorigenesis experiment effects of RGMB-AS1 on the malignant phenotype of GC cells. were conducted te. ts being poncogenic actions of RGMB-AS1 in GC were elucidated The molecular eve through ellular tionation, RNA immunoprecipitation assay, bioinformatics analysis aciferas and reporte assay.

**Insults:** *JPAPP* 4S1 apregulation was confirmed in GC tissues and cell lines. Higher *RGn* 451 expression was associated with adverse clinical parameters and negatively correlate with patient overall survival. *RGMB-AS1* knockdown inhibited GC cell proliferation, facility of apoptosis, and reduced migration and invasion in vitro. Further experiments realed that *RGMB-AS1* knockdown decreased the tumor growth of GC cells in vivo. Meannistically, *RGMB-AS1* functioned as a competing endogenous RNA upregulating histone deacetylase 4 (HDAC4) by sponging microRNA-574 (miR-574). Rescue experiments indicated that miR-574 inhibition and HDAC4 reintroduction reversed the effects of the *RGMB-AS1* knockdown on GC cells.

**Conclusion:** The *RGMB-AS1*–miR-574–HDAC4 regulatory network contributes to the malignancy of GC, thereby offering a novel target for the diagnosis, prognosis, and/or treatment of GC.

Keywords: tumor therapy, gastric cancer, miR-574, RGMB-AS1, histone deacetylase 4

#### Introduction

Gastric cancer (GC), which originates in the gastric mucosa, is the fourth most prevalent human cancer and its mortality rate ranks second among cancerassociated mortality rates globally.<sup>1,2</sup> Approximately 1.033 million new GC cases and 783 000 GC-related deaths worldwide are estimated for 2018, according to 2018 GLOBOCAN statistics.<sup>2</sup> Despite the tremendous achievements in GC diagnosis and therapy, its treatment efficacy at an advanced stage remains poor, with

OncoTargets and Therapy 2020:13 1691-1704

1691

OncoTargets and Therapy downloaded from https://www.dovepress.com/ For personal use only.

Xiaodong Wang Xin Chen Yueli Tian Dongqiang Jiang Ying Song

Department of Gastroenterology and Digestive Endoscopy Center, The Second Hospital of Jilin University, Changchun, Jilin 130041, People's Republic of China



Correspondence: Ying Song Department of Gastroenterology and Digestive Endoscopy Center, The Second Hospital of Jilin University, 218 Ziqiang Road, Changchun, Jilin 130041, People's Republic of China Email yingsong\_636@163.com



© 2020 Wang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-n/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission for Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). a 5-year overall survival rate of only approximately 20–30%.<sup>3</sup> These poor clinical outcomes are attributable to multiple factors including a lack of early diagnosis in addition to recurrence and local/distant metastasis even following surgical resection.<sup>4</sup> Although the incidence of GC is closely related to *Helicobacter pylori* infection, diet, smoking, and obesity,<sup>5</sup> its pathogenesis is complicated and the mechanisms underlying GC initiation and progression remain largely unknown. Hence, it is critical to elucidate the mechanisms responsible for the malignancy of GC and to identify novel effective targets applicable to the diagnosis and therapy of GC, with the aim of improving patient prognosis.

Long noncoding RNAs (lncRNAs) are a series of recently discovered RNA molecules greater than 200 nucleotides in length.<sup>6</sup> These transcripts do not encode proteins but are implicated in the modulation of gene expression at transcriptional and post-transcriptional levels.<sup>7</sup> Previously, lncRNAs have been regarded as "noise" in genome transcription; nevertheless, increasing numbers of studies have revealed their contribution to nearly all parameters of biological and pathological processes.<sup>8-10</sup> Substantial research has demonstrated an alteration of lncRNA expression in GC, with some of the identified lncRNAs performing a vital function regulating gastric carcinogenesis and GC progression.<sup>11-</sup> Notably, lncRNAs may serve as either tumor supp sors or oncogenic molecules and participate in the egulat n of 14-16 malignant characteristics of GC during GC ogressi

MicroRNAs (miRNAs) comprise anoth roup of noncoding RNA molecules, of 25 nucle ides in length.<sup>17</sup> They can directly interest with the 3' untranslated regions (3'-UTRs) of their to get mRNAs has base-pairing manner, thereby causing inRNA degradation and/or translational suppression. A griet of mRNAs have also been found to be abnormally excessed in Jaman cancers, such sregulation of wire NAs in GC has been as GC. The functionalk characterized and found to exert important actions on uple pathophysiological parameters. shows that lncRNAs act as competing Increasing eviden endogenous RNAs (CRNAs) toward specific miRNAs and thereby positively modulate the expression of these mRNAs. Consequently, the resultant lncRNA-miRNAmRNA regulatory network may become a diagnostic biomarker and therapeutic target in GC.

LncRNA *RGMB-AS1* performs an important function in the genesis and progression of multiple human cancers.<sup>18–21</sup> Nevertheless, the expression and functions of *RGMB-AS1* in GC remained unknown. Therefore, this study was designed to determine the expression level and detailed involvement of *RGMB-AS1* in GC. Moreover, we thoroughly examined the mechanism by which *RGMB-AS1* promotes GC progression.

#### Materials and Methods Collection of Tissue Samples

The study protocol was approved by the Ethics Committee of The Second Hospital of Jilin University. All the participants signed an informed consent form. Tumor tissue samples and adjacent normal tissues where chained in The Second Hospital of Jilin University from 67 patients with GC who had not undergone preoperative radioth dapy, chemotherapy, or other antice cer treatments. Note of these patients had a diagnosity of other types of encer. Following surgical resection, all high assue samples were quickly immersed in liqua nitrogen and theratored at -80 °C.

#### Cell Lines

A no nal human gastric ep thelial cell line (GES-1) and four human GC cell lines (MKN-45, MGC-803, BGC-823, and AGC were purchased from the American Type Culture Collect (Marcussas, VA, USA). A culture medium consisthuman f Dulbecco's modified Eagle's medium (DMEM; cat. N.1249-015), 10% fetal bovine serum (FBS; cat. No.10091148), 100 U/mL penicillin, and 100 µg/mL streptotycin (cat. No.15070063; all from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was utilized for cell cultivation. All cells were kept at 37 °C in an incubator containing an atmosphere of humidified 95% air and 5% CO<sub>2</sub>.

#### Oligonucleotides, Plasmids, and Cell Transfection

The small interfering RNAs (siRNAs) targeting *RGMB-AS1* (si-RGMB-AS1) and negative control siRNA (si-NC) were synthesized by RiboBio Co., Ltd. (Guangzhou, China). The si-RGMB-AS1 sequence was 5'- GGCTCAATTACCGAC ACAGTTCAAG-3' and the si-NC sequence was 5'-UUC UCCGAACGUGUCACGUTT-3'. The agomirs for miR-574 (agomir-574 and agomir-NC), and miRNA antagomirs (antagomir-574 and antagomir-NC) were all purchased from GenePharma Co., Ltd. (Shanghai, China). The agomir-574 sequence was 5'-CACGCUCAUGCACACACCCACA-3', the agomir-NC sequence was 5'-UUCUCCGAACGUGUCA CGUTT-3', antagomir-574 sequence was 5'-UGUGGGUGU GUGCAUGAGCGUG -3', and the antagomir-NC sequence was 5'-CAGUACUUUUGUGUAGUACAA-3'. HDAC4

overexpression plasmid pcDNA3.1-HDAC4 (hereafter: pc-HDAC4), was chemically synthesized by Generay (Shanghai, China), and the empty pcDNA3.1 vector served as the control.

Cells growing in the logarithmic (log) phase were seeded in 6-well plates and cultured at 37 °C overnight. All abovementioned siRNAs, agomirs, antagomirs, and plasmids were introduced into cells using Lipofectamine<sup>TM</sup> 2000 (cat. No.11668019; Invitrogen; Thermo Fisher Scientific) in accordance with the relevant protocols.

# RNA Extraction and Reverse-Transcription Quantitative PCR (RT-qPCR)

The TRIzol<sup>®</sup> reagent (cat. No.15596026; Invitrogen; Thermo Fisher Scientific) was employed for isolation of total RNA from tissues or cells. After quality verification on a NanoDrop<sup>™</sup> 2000 spectrophotometer (Invitrogen; Thermo Fisher Scientific), total RNA was reverse-transcribed into complementary DNA (cDNA) by means of the TaqMan MicroRNA Reverse Transcription Kit (cat. No. 4366596; Applied Biosystems, Foster City, CA, USA), and the obtained cDNA was then subjected to qPCR for the measuren t of miR-574 expression using the TaqMan MicroRNA Ass. Kit (cat. No. 4427975; Applied Biosystems). MiR-574 expression was normalized to that of U6 small nuclear NA. To det mine *RGMB-AS1* and HDAC4 expression, reverse transcrip tion was conducted using the Primes pipt Regent Knowat. No. RR037A; TaKaRa Biotectology Cont.td., Dalian, per rmed by mons of the China), after which qPCR y SYBR Premix Ex Taq<sup>T</sup> kit (cat. RR420A; TaKaRa Biotechnology). GAP A served as the intenal reference for *RGMB-AS1* and  $H_{1}C4$ .

The primers were weighed as follows: RGMB-AS1, 5'-A GTGGGC' (ACCTCAA, GTT, -3' (forward) and 5'-GAGC TGCCA (GAAT, AATCCO, 3' (reverse); HDAC4, 5'-AGA ATGGC), TC (TGTOG-, C-3' (forward) and 5'-ATCTTGCT CACGCTCA, CCT-3' (reverse); and GAPDH, 5'-GAGTCC ACTGGCGTCT, C-3' (forward) and 5'- GATGATCTTGA GGCTGTTGTC-3' (reverse). Relative gene expression was analyzed using the  $2^{-\Delta\Delta Cq}$  method.

#### Cell Counting Kit-8 (CCK-8) Assay

At 24 h post-transfection, cells were seeded in 96-well plates at a density of  $2 \times 10^3$  cells per well. Cell proliferation was evaluated by the addition of 10 µL of the CCK-8 solution (cat. No. CK04; Dojindo Laboratories, Kumamoto,

Japan) into each well. After an additional 2 h incubation, absorbance was measured at 450 nm wavelength using a Microplate Spectrophotometer (BioTek, Winooski, VT, USA). The CCK-8 assay was carried out at four time points (0, 24, 48, and 72 h after seeding), and the growth curves were plotted with time points on the X-axis and absorbance values on the Y-axis.

#### Flow-Cytometric Analysis of Apoptosis

The apoptotic status of GC cells was tested using the Annexin V Fluorescein Isothiocyanate (FITC) cooptosis Detection Kit (cat. No. 640914; Biolegend, Sau Diego, Co USA). In particular, transfected cells were havested with Eu TA-free 0.25% trypsin, rinsed twice with ce-colo chosphate suffered saline, centrifuged at 4 °C, then the supernal of the as decanted. The transfected cells were resurrended in 100  $\mu$ L of 1× binding buffer and 5  $\mu$ C Annex 04-FITC and 5  $\mu$ L propidium iodide solution were unded for a table staining of apoptotic cells. After 15 min inclusion in the dark, the percentage of apoptotic tice to was determined on a FACScan flow cytometer.

#### ranswel Migration and Invasion Assays

evaluate effects of the miRNA on cellular invasive 24-well insert Transwell chambers (cat. No. capac. 1993) coated with Matrigel (cat. No. 356231; both from BD Biosciences, San Jose, CA, USA) were applied for the Transwell invasion assay. Transfected cells were harvested through digestion with 0.25% trypsin and rinsed twice with phosphate-buffered saline. After centrifugation, the supernatant was discarded and the transfected cells were resuspended in serum-free DMEM. A total of 100 µL of the suspension containing  $5 \times 10^4$  cells was transferred to the upper compartment of each chamber, whereas 600 µL of DMEM supplemented with 20% FBS was placed in the bottom compartments. After cultivation for 24 h at 37 °C, the cells remaining in the upper chamber were carefully removed with a cotton swab, whereas the invasive cells were fixed with 4% polyformaldehyde and stained with 0.5% crystal violet. The stained cells were imaged and counted under an inverted microscope (IX83; Olympus, Tokyo, Japan). Similar experimental procedures were conducted to determine the cellular migratory ability, except that the chambers were not precoated with Matrigel.

#### In vivo Tumorigenesis Experiment

Animal maintenance and experimental steps were approved by the Animal Care and Use Committee of The Second Hospital of Jilin University. All experimental steps were performed in compliance with the Animal Protection Law of the People's Republic of China-2009 for experimental animals. Female nude mice at the age of 4–6 weeks were purchased from Shanghai Laboratory Animal Center (Shanghai, China). Cells transfected with either si-RGMB-AS1 or si-NC were harvested at 24 h of cultivation and injected subcutaneously into a flank of the mice. Measurements of the width and length of the resultant tumor xenografts were carried out every five days, and the volume was calculated via the following formula:  $0.5 \times$ length × (width)<sup>2</sup>. The tumor xenografts were allowed to grow in vivo for 30 days. On day 30, all the mice were euthanized by cervical dislocation and the tumor xenografts were excised, weighed, and subjected to RT-qPCR and Western blotting analyses.

#### Subcellular Fractionation

The PARIS Kit (cat. No. AM1921; Invitrogen; Thermo Fisher Scientific) was employed to collect and separate cytoplasmic and nuclear fractions of GC cells. RNA was isolated from the cytoplasmic and nuclear fractions using the TRIzol<sup>®</sup> reagent and subjected to RT-qPCR analysis to evaluate *RGMB-AS1* distribution within GC cells.

#### RNA Immunoprecipitation (RIP) Assay

The Magna RNA-binding Protein Immunopresident n Kit (cat. No. 17-701; Millipore, Billerica, MA, SA) w utilized to perform the RIP assay. Cells were rike d th CC W phosphate-buffered saline, trypsing a, and the ted with RIP lysis buffer. The cell extract the collected a lincubated with magnetic beads onjugated th human anti-Argonaute2 (AGO2) or ti-IgG antibodic (Millipore). The magnetic beads we e wash and then incubated with protein Finally, RT-qPCR proteinase K in order to 7 ntificion *CAGMB-AS1* and miRwas carried out JI 4 574 in the correcipite of RNA mples.

## Bioinformatics Analysis and Luciferase Reporter Assa

The interaction between *RGMB-AS1* and miRNA was predicted using starBase 3.0 software (<u>http://starbase.sysu.</u> <u>edu.cn/</u>). TargetScan (<u>http://www.targetscan.org</u>) and starBase 3.0 were applied to predict the putative targets of miR-574. Wild-type (wt) *RGMB-AS1* that contains a predicted miR-574–binding sequence and mutant (mut) *RGMB-AS1* were chemically synthesized by GenePharma Co., Ltd. and integrated into the pMIR-REPORT plasmid

(cat. No. AM5795; Invitrogen; Thermo Fisher Scientific) to respectively generate reporter plasmids pMIR-wt-RGMB-AS1 and pMIR-mut-RGMB-AS1. The reporter plasmids intended for determining the interaction between miR-574 and HDAC4 mRNA, namely, pMIR-wt-HDAC4 and pMIR-mut-HDAC4, were constructed via similar experimental steps. For the reporter assay, cotransfection of either the wt or mut reporter plasmid and either agomir-574 or agomir-NC into GC cells was performed using Lipofectamine<sup>™</sup> 2000. After 48 h cultivation, the Dual Luciferase Reporter Assay Kit (cat. Nor 51910; Promega, Madison, WI, USA) was used to dantify luciferase activity. Renilla luciferase activity erved as the ontrol for firefly luciferase activity.

#### Protein Isolation and Vestern Blotting

Transfected MGC 303 and AGS cc 3 were lysed with RIPA buffer No. POOR Beyotime Institute of Biotechnology, Shak hai, China). The Bicinchoninic Acid Kit (cat. 10. P0009; Beyotime Institute of Protein chnology) was utilized for the quantification of total Biot protin. Identical nounts of protein were separated by 10% Ifate polyacrylamide gel electrophoresis sodiu dodecyl onto polyvinylidene difluoride membranes. and trans. Pr incubation with primary antibodies overnight at 4 °C, e membranes were blocked with 5% nonfat dry milk at oom temperature for 2 h. Next, after incubation with horsedish peroxidase-conjugated goat anti-mouse IgG secondary antibody (cat. No. ab205719; dilution 1:1000; Abcam, Cambridge, UK), the SuperSignal West Femto Maximum Sensitivity Substrate (cat. No.34096; Thermo Fisher Scientific) was applied to visualize the protein signals on the membranes. The anti-HDAC4 antibody (cat. No. ab234084; dilution 1:1000; Abcam) was used herein and GAPDH (cat. No. ab9484; dilution 1:1000; Abcam) served as a loading control.


#### Statistical Analysis

Data are presented as the mean  $\pm$  standard deviation. The Chi-squared test was performed to determine the relationship between *RGMB-AS1* and clinical parameters among the patients with GC. Student's *t* test was conducted to analyze the differences between two groups. Differences among multiple groups were evaluated by one-way analysis of variance followed by Tukey's test. Survival curves were plotted using the Kaplan–Meier method and analyzed by the log rank test. The expression correlation between *RGMB-AS1* and miR-574 among the GC tissue samples was assessed by Spearman correlation analysis. MiR-574 and HDAC4 expression correlation was also evaluated via Spearman correlation analysis. P < 0.05 was assumed to indicate a statistically significant difference.

#### Results

### High Expression of RGMB-AS1 Correlates with Adverse Clinical Parameters and Worse Clinical Outcomes of GC

First, we measured the expression of *RGMB-AS1* in 67 pairs of GC tissue samples and adjacent normal tissues. The results of RT-qPCR analysis indicated that *RGMB-AS1* expression was higher in GC tumors than that in adjacent normal tissues (Figure 1A, P < 0.05). We also measured *RGMB-AS1* expression in four GC cell lines (MKN-45, MGC-803, BGC-823, and AGS) and in normal human gastric epithelial cells (GES-1) via RT-qPCR. All four tested GC cell lines manifested higher expression of *RGMB-AS1* than that in GES-1 cells (Figure 1B, P < 0.05).



**Figure 1** *RGMB-AS1* is upregulated in GC and this high expression inversely correlates with patient survival. (**A**) Expression levels of *RGMB-AS1* in 67 pairs of GC tissue samples and adjacent normal tissues were analyzed via RT-qPCR. RT-qPCR was repeated at least three times. \*P < 0.05 vs adjacent normal tissues. (**B**) RT-qPCR analysis was conducted to determine *RGMB-AS1* expression in four GC cell lines (MKN-45, MGC-803, BGC-823, and AGS) and in normal human gastric epithelial cells (GES-1). RT-qPCR was repeated at least three times.\*P < 0.05 vs GES-1. (**C**) We subdivided 67 patients with GC into either high- or low-*RGMB-AS1* expression groups. The correlation of *RGMB-AS1* expression with overall survival among the patients with GC was evaluated using the Kaplan–Meier method and log rank test. P = 0.02.

According to the median value of RGMB-AS1 among the GC tissue samples, all 67 patients with GC were classified into high- or low-RGMB-AS1 expression groups, and then the association between RGMB-AS1 expression and clinical parameters among the patients with GC was assessed. An elevated RGMB-AS1 level closely correlated with tumor size (P = 0.026), TNM stage (P = 0.043), and lymph node metastasis (P = 0.029; Table 1). Furthermore, Kaplan–Meier analysis along with the log rank test was conducted to evaluate whether the expression of RGMB-AS1 correlated with overall survival of the patients under study. Patients with GC in the high-RGMB-AS1 expression gr shorter overall p exhibit survival than those in the low GMB-AS1 e ression group (Figure 1C, P = 0.02). Quartall, Rev B-AS1 as found to be aberrantly overexpressed in GC and Serration may be involved in GC procession

Knockdown of RGABASI Restricts the Proliferation, Migration, and Invasion and Formates the Apoptosis of GC Cells in vitro o study the effects of *RGMB-AS1* on the GC tumor henotype, SRGMB-AS1 was synthesized and transfered into AGC-803 and AGS cells. RT-qPCR analysis

Table I Associations Between RGMB-AS1 Expression and Clinical
Parameters of Patients with GC (n=67)

Clinical Parameters	RGMB-ASI Expression		Р
	High Group	Low Group	
Age			0.460
< 50 years	16	12	
≥50 years	18	21	
Sex			0.218
Female	11	16	
Male	23	17	
Tumor size			0.026
< 3 cm	15	24	
≥3 cm	19	9	
Histological type			0.131
Well and Moderate	25	18	
Poor	9	15	
TNM stage			0.043
I–II	17	25	
III–IV	17	8	
Lymph node metastasis			0.029
Negative	20	28	
Positive	14	5	

verified the successful knockdown of *RGMB-AS1* in both cell types (Figure 2A, P < 0.05). MGC-803 and AGS cells were also transfected with or without si-NC. After transfection, expression of *RGMB-AS1* was detected by means of RT-qPCR. Transfection with si-NC did not affect the expression of RGMB-AS1 (<u>Supplementary Figure 1A</u>). Next, the CCK-8 assay was performed to evaluate cellular proliferation. The results suggested that transfection with si-RGMB-AS1 led to evident suppression of MGC-803 and AGS cell proliferation (Figure 2B, P < 0.05). In

addition, our results revealed that the knockdown of *RGMB-AS1* markedly promoted the apoptosis of MGC-803 and AGS cells (Figure 2C, P < 0.05), as evidenced by the flow-cytometric analysis. Furthermore, Transwell cell migration and invasion assays were conducted to test whether *RGMB-AS1* is involved in GC cell metastasis in vitro. A reduction in *RGMB-AS1* expression obviously impaired the migratory (Figure 2D, P < 0.05) and invasive abilities (Figure 2E, P < 0.05) of MGC-803 and AGS cells. Collectively, these results implied that *RGMB-AS1* 





Figure 2 Effects of *RGMB-AS1* knockdown on GC cell proliferation, apoptosis, migration, and invasion in vitro. (**A**) The expression of *RGMB-AS1* was measured by RT-qPCR in MGC-803 and AGS cells following either si-RGMB-AS1 or si-NC transfection. RT-qPCR was repeated at least three times. \*P < 0.05 vs si-NC. (**B**) The effect of *RGMB-AS1* knockdown on the proliferative capacity of MGC-803 and AGS cells was examined using the CCK-8 assay. CCK-8 assay was repeated at least three times. \*P < 0.05 vs si-NC. (**B**) The effect of *RGMB-AS1* knockdown on GC cell apoptosis was performed on MGC-803 and AGS cells transfected with either si-RGMB-AS1 or si-NC to assess the effect of *RGMB-AS1* knockdown on GC cell apoptosis. Flow-cytometric analysis was repeated at least three times. \*P < 0.05 vs si-NC. (**D**, **E**) The migratory and invasive abilities of *RGMB-AS1* deficient MGC-803 and AGS cells were evaluated using Transwell migration and invasion assays. Transwell migration and invasion assays were repeated at least three times. \*P < 0.05 vs si-NC.

performs oncogenic activities during the growth and metastasis of GC cells in vitro.

# RGMB-ASI Acts as a ceRNA on miR-574 in GC Cells

Some studies have shown that lncRNAs work as ceRNAs for specific miRNAs to modulate their expression and

functions. To elucidate the mechanisms behind the oncogenic actions of *RGMB-AS1* in GC, subcellular localization of *RGMB-AS1* was first characterized in MGC-803 and AGS cells. The results indicated that the majority of *RGMB-AS1* was located in the cytoplasm of MGC-803 and AGS cells (Figure 3A), indicating that this lncRNA may regulate its target at the post-transcriptional levels.



**Figure 3** *RGMBAS1* serves as a ceRNA for miR-574 in GC cells. (**A**) The distribution of *RGMBAS1* between the cytoplasmic and nuclear compartments of MGC-803 and AGS cells was analyzed by subcellular fractionation followed by RT-qPCR. The assay was repeated at least three times. (**B**) Schematic description of wild-type and mutant binding sites for miR-574 in *RGMBAS1*. (**C**) The luciferase reporter assay was performed to assess the interaction between *RGMBAS1* and miR-574 in GC cells. The luciferase activity in MGC-803 and AGS cells following cotransfection of either pMIR-wt-RGMB-AS1 or pMIR-mut-RGMB-AS1 and either agomir-574 or agomir-NC was analyzed by means of the Dual Luciferase Reporter Assay Kit. Luciferase reporter assay was repeated at least three times. \*P < 0.05 vs agomir-574. (**D**) The RIP assay was performed on MGC-803 and AGS cells, and coprecipitated RNA was extracted and then subjected to RT-qPCR analysis. RIP assay was queatified by RT-qPCR. RT-qPCR was repeated at least three times. \*P < 0.05 vs igG. (**E**) Following transfection of either si-RGMB-AS1 or si-NC into MGC-803 and AGS cells, relative expression of miR-574 was quantified by RT-qPCR. RT-qPCR was repeated at least three times. \*P < 0.05 vs ig-QC. (**F**) RT-qPCR analysis was conducted to determine the expression of miR-574 in the 67 pairs of GC tissue samples and adjacent-normal-tissue samples. (**G**) Expression correlation between *RGMB-AS1* and miR-574 levels among the 67 GC tissue samples was evaluated using Spearman correlation analysis. r = -0.5446, P < 0.0001.

Bioinformatics analysis revealed that miR-574, a GCrelated tumor suppressor,<sup>22,23</sup> might constitute a potential target of RGMB-AS1 (Figure 3B). To validate this prediction, a luciferase reporter assay was conducted to evaluate the binding of RGMB-AS1 to miR-574 in GC cells. Either plasmid pMIR-wt-RGMB-AS1 or pMIR-mut-RGMB-AS1 was introduced into MGC-803 and AGS cells with either agomir-574 or agomir-NC. Cotransfection with pMIR-wt-RGMB-AS1 and agomir-574 resulted in an obvious decrease in luciferase activity in MGC-803 and AGS cells (P < 0.05), whereas the luciferase activity remained unaltered when these cells were cotransfected with pMIRmut-RGMB-AS1 (Figure 3C). In addition, the direct interaction between RGMB-AS1 and miR-574 was examined using the RIP assay. The results revealed that miR-574 and RGMB-AS1 from lysates of MGC-803 and AGS cells were significantly enriched on AGO2-bound beads compared with the IgG control (Figure 3D, P < 0.05).

Next, we assessed the expression of miR-574 in RGMB-AS1-deficient MGC-803 and AGS cells. RT-qPCR analysis confirmed that the RGMB-AS1 knockdown obviously enhanced the expression of miR-574 in MGC-803 and AGS cells (Figure 3E, P < 0.05). In addition, we tested the expression correlation between miR-574 and RGMB-ASI GC tissue samples. Consistent with the results of othe studies.<sup>22,23</sup> miR-574 was markedly downregulat in the GC tissue samples relative to the levels in addicent i rmal tissues (Figure 3F, P < 0.05). Furthermore, the expression of the second sec miR-574 manifested an inverse correction . RGMB-AS1 expression in the 67 GC tisse pamples (P. re 3G;r = -0.5446, P < 0.0001). In mmal *RGMB-AM* was found to function as a ceR for miR-574 GC cells.


# MiR-574 Inhibits the falignent Properties of GC Cells in aitro and Directly Targets HDAC4 mRN/ in GC Cells

To explore the balance of miR-574 in GC, either agomir-574 or agomir-NC was transfected into GC cells and the influence of hdR-574 upregulation on the malignant properties of GC cells was investigated. First, the upregulation of miR-574 in agomir-574–transfected MGC-803 and AGS cells was verified by RT-qPCR (Figure 4A, P < 0.05). Transfection with agomir-574 significantly decreased MGC-803 and AGS cell proliferation (Figure 4B, P < 0.05), increased apoptosis (Figure 4C, P < 0.05), and impaired migration (Figure 4D, P < 0.05) and invasion (Figure 4E, P < 0.05) in vitro. Collectively, these results confirmed that miR-574 exerts a tumor-suppressive action on the malignancy of GC cells in vitro.

We next attempted to uncover the mechanism of action of this miRNA. Bioinformatics analysis suggested that HDAC4 contains highly conserved binding sequences for miR-574 (Figure 4F). To test whether miR-574 is implicated in the modulation of HDAC4 expression, RT-qPCR and Western blotting were performed to respectively measure HDAC4 mRNA and protein expression in MGC-803 and AGS cells following either agomir-574 or agomir-NC transfection. The results showed that upregulation of 574 markedly decreased HDAC4 mRNA (Figure 6, P < 0.05, and protein (Figure 4H, P < 0.05) levels in box cell types. addition, HDAC4 mRNA expression A GC tiss, sample and adjacent normal tissues (n = 1) was desired  $\sqrt{T-qPCR}$ . The expression of HDAC me A as considerably higher in the GC tissue sames (Figure 1, P 0.05), manifesting a negative created with mike 4 expression (Figure 4J; r = -0.5747, P < 0.01). Finally, the luciferase reporter was carried out to ascertain whether miR-574 can assay directly to DAC4 mRNA. miR-574 overexpression bin decr sed the lucit rase activity generated by plasmid pMIRwt-HD. 14. (P 0.05) in MGC-803 and AGS cells. In st, the luciferase activity generated by plasmid pMIRat-HDAC4 remained unaltered following agomir-574 cotransfection (Figure 4K). These data provided evidence at HDAC4 is a direct target gene of miR-574 in GC cells.

### RGMB-ASI Sponges miR-574 to Increase HDAC4 Expression in GC Cells

We next aimed to test whether HDAC4 expression can be modulated by RGMB-AS1 via the sponging of miR-574. Hence, either si-RGMB-AS1 or si-NC was transfected into MGC-803 and AGS cells, and HDAC4 expression was quantified at the mRNA and protein levels. The results indicated that the mRNA (Figure 5A, P < 0.05) and protein levels (Figure 5B, P < 0.05) of HDAC4 were decreased by RGMB-AS1 knockdown in MGC-803 and AGS cells. In addition, MGC-803 and AGS cells were transfected with or without si-NC. Expression levels of miR-574 and RGMB-AS1 protein were respectively detected by RT-qPCR and Western blotting. The results displayed that transfection with si-NC did not alter the expression of miR-574 and RGMB-AS1 protein compared with that in cells transfected without si-NC (Supplementary Figure 1B and C)




A to inhibi Figure 4 MiR-574 directly targets HDAC4 proliferation, migration, and invasiveness and promote the apoptosis of GC cells in vitro. (A) RT-qPCR confirmed the efficiency of agomir-574 tra on in MGC-803 AGS cells. \*P < 0.05 vs agomir-574. RT-qPCR was repeated at least three times. (**B, C**) The proliferation and apoptotic status of miR-574-overea essing C-803 and AG. Ils were respectively investigated using the CCK-8 assay and flow cytometry. \*P < 0.05 vs agomir-574. three times. (**D, E**) The effects of miR-574 upregulation on the migratory and invasive abilities of MGC-803 and AGS CCK-8 assay and flow cytometry were repeated at igration and invasi cells were verified using Transwe ssays. Transwell migration and invasion assays were repeated at least three times. \*P < 0.05 vs agomir-574. (F) The che 3'-UTR of HDAC4 m binding site for miR-574 with A as predicted by bioinformatics analysis. The mutant binding sequences are also shown. (G, H) mRNA and GC-803 2 protein levels of HDAC4 AGS cells following either agomir-574 or agomir-NC transfection were assessed by RT-qPCR and Western blotting, respectively. RT-qPCR and Western blo eated at least three times. \*P < 0.05 vs agomir-574. (I) RT-qPCR analysis was carried out to measure HDAC4 mRNA expression in 67 were ent normal sues. RT-qPCR was repeated at least three times.\*P < 0.05 vs adjacent normal tissues. (J) Spearman correlation analysis pairs of GC tissue samples a was conducted f the co ation be ren miR-574 and HDAC4 mRNA expression among the 67 GC tissue samples. r = –0.5747, P < 0.0001. (K) Luciferase activity MGC-8 viously transfected with either agomir-574 or agomir-NC along with either pMIR-wt-HDAC4 or pMIR-mut-HDAC4, with the was detected and AG. n the bind of miR-574 , thin the 3'-UTR of HDAC4 mRNA. Luciferase reporter assay was repeated at least three times.\*P < 0.05 vs agomir-574. aim to co


Furthermore, the expression of HDAC4 was analyzed in MGC-803 and A/S cells following cotransfection with si-RGMB-AS1 and either antagomir-NC or antagomir-574. First, RT-qPCR analysis confirmed that the transfection with antagomir-574 successfully reduced miR-574 expression in both cell types (Figure 5C, P < 0.05). Notably, the decrease in HDAC4 mRNA (Figure 5D P < 0.05) and protein amounts (Figure 5E, P < 0.05) under the influence of *RGMB-AS1* knockdown was reversed by cotransfection of MGC-803 and AGS cells with antagomir-574. These

results implied that *RGMB-AS1* serves as a ceRNA that increases HDAC4 expression in GC cells by competing for miR-574.

# The RGMB-ASI-miR-574-HDAC4 Pathway Promotes GC Progression in vitro

Rescue assays were carried out to identify the functions of the *RGMB-AS1*–miR-574–HDAC4 pathway in the malignancy of





GC cells. Toward this end, either antagomir-574 or antagomir-NC along with si-RGMB-AS1 were transfected into MGC-803 and AGS cells. The CCK-8 assay and flow-cytometric analysis of apoptosis confirmed that the suppression of d proliferation (Figure 6A, P < 0.05) and promotion of apoptosi (Figure 6B, P < 0.05) by the *RGMB-AS1* knock were reversed by antagomir-574 cotransfection into 1GC-8 and AGS cells. Transwell migration and invasion says that cell migratory (Figure 6C, P < 0.05) e abilities and inv RGMB-A (Figure 6D, P < 0.05) were impair knockdown albeit recovered in MGC-803 and S cells by means of antagomir-574 cotransfer Jn.

In addition, rescue experimenter vere performed on MGCg creansfection of si-RGMB-AS1 803 and AGS cells follow or por DAC4 The transfection effiand either pcDN ciency is show a in Fig re 6E (1 0.05). As anticipated, the MB-A effects of A lown on GC cell proliferation (), apoptosis (Figure 6G, P < 0.05), migra-(Figure 6F. P < tion (Figure 6H, P 05), and invasion (Figure 6I, P < 0.05) were attenuated by HDAC4 reintroduction. Overall, the above results confirmed that knockdown of RGMB-AS1 decreased GC progression via the miR-574-HDAC4 axis.


## RGMB-ASI Knockdown Inhibits Tumor Growth of GC Cells in vivo

MGC-803 cells transfected with either si-RGMB-AS1 or si-NC were inoculated into the flank of nude mice to test the

nce of RGMB-AS1 on the tumor growth of GC cells influ o. It was observed that the volume (Figure 7A and B, in v 5) and y Ight (Figure 7C, P < 0.05) of the tumor P < Venografts derived from si-RGMB-AS1-transfected MGC-80 were significantly lower than those of xenografts ormed by si-NC-transfected cells. In addition, a decrease in *GMB-AS1* (Figure 7D, P < 0.05) and an increase in miR-74 (Figure 7E, P < 0.05) amounts were noted in the tumor xenografts from the si-RGMB-AS1 group. Furthermore, HDAC4 mRNA (Figure 7F, P < 0.05) and protein levels (Figure 7G, P < 0.05) in the tumor xenografts derived from MGC-803 cells transfected with si-RGMB-AS1 were lower than those in the si-NC group. Taken together, these findings indicated that a reduction in RGMB-AS1 expression lowered HDAC4 expression through decreased sponging of miR-574 in GC cells, resulting in the inhibition of tumor growth in vivo.

#### Discussion


Recently, increasing evidence indicates that a large number of lncRNAs are dysregulated in GC.<sup>24–26</sup> The dysregulation of lncRNAs is implicated in the regulation of various malignant cytological behaviors during gastric carcinogenesis and GC progression.<sup>27–29</sup> Therefore, comprehensive research into the lncRNA-based regulatory network in GC may facilitate the discovery of effective targets for the diagnosis and treatment of this cancer. Although a variety



**Figure 6** *RGMB-AS* involved in the regulation of malignant properties of GC cells through the miR-574–HDAC4 axis. (**A**, **B**) MGC-803 and AGS cells were cotransfected with si-RGMB-AS1 and ther antagomir-NC or antagomir-574. Cell proliferation and apoptosis were measured using the CCK-8 assay and flow cytometry, respectively. CCK-8 assay and flow cytometry analysis were repeated at least three times.\*P < 0.05 vs si-NC. \*P < 0.05 vs si-RGMB-AS1+antagomir-NC. (**C**, **D**) Transwell migration and invasion assays were carried out to examine the migration and invasiveness of the aforementioned cells. Transwell migration and invasion assays were repeated at least three times. \*P < 0.05 vs si-NC. #P < 0.05 vs si-NC. #P < 0.05 vs si-NC. #P < 0.05 vs si-RGMB-AS1+antagomir-NC. (**E**) Western blotting was performed for determining HDAC4 protein expression in MGC-803 and AGS cells following transfection of plasmid pc-HDAC4 or the empty pcDNA3.1 vector. Western blotting was repeated at least three times. \*P < 0.05 vs pcDNA3.1 (**F**-1) Either pc-HDAC4 or pcDNA3.1 along with si-RGMB-AS1 were transfected into MGC-803 and AGS cells. Subsequently, the CCK-8 assay, flow-cytometric analysis of apoptosis, and Transwell migration and invasion assays were carried out to respectively investigate the proliferation, apoptosis, migration, and invasion assays were carried cells. All experiments were repeated at least three times.\*P < 0.05 vs si-NC. #P < 0.05 vs si-NC = 0.05 vs

of lncRNAs in GC have been well-studied, numerous other lncRNAs remain to be further explored in detail. In the present study, a novel GC-specific lncRNA, *RGMB-AS1*,

was identified. We measured its expression profile, determined detailed functions, and illustrated the mechanism of action of *RGMB-AS1* in GC.



or xenografts Figure 7 RGMB-AS1 knockdown slows the tumor growth of GC cells in vivo. (A) Representative images of si-RGMB-ASI and si-NC. (B) gro Volumes of the tumor xenografts were measured following inoculation, and a growth curve was plotted according at least three times. \*P < 0.05 vs The assay was r si-NC. (C) After excision of tumor xenografts, the tumor weights were determined and analyzed. The ass was rep d at least three times. \*P < 0.05 vs si-NC. (**D, E**) RTts. \*P < 0.05 vs si-NC. RT-qPCR was repeated at qPCR analysis was performed to measure the expression levels of RGMB-AS1 and miR-574 in the excised tumor xend least three times. (F, G) Relative mRNA and protein levels of HDAC4 in the excised tumor xenge re measured v qPCR and Western blotting, respectively. RTqPCR and Western blotting were repeated at least three times. \*P < 0.05 vs si-NC.

RGMB-AS1 is overexpressed in laryngeal squamous cell carcinoma and shows a significant correlation with tun stage and lymph node metastasis.<sup>18</sup> Patients with larynge squamous cell carcinoma showing high RGMB-ASL expres sion exhibit worse overall-survival and disease ree st vival rates than those of patients with RGN - 451 expression.<sup>18</sup> RGMB-AS1 is upregulat cancer in . and papillary thyroid carcinoma.<sup>20</sup> / MB-AS1 up gulation in lung cancer is related to differnitiat. TNM star, and lymph node metastasis.<sup>19</sup> Incontrast, RGMAS1 is downregulated in hepatocellule carcinoma and its downregulation shows an obvious association y a clinical stage, tumor size, and metastasis.<sup>21</sup> In addition (GMB-/ / has been validated as an independent predictor of the clinical outcomes of Jular carcinoma.<sup>21</sup> Nonetheless, relapatients with hepator vn regarding its expression pattern and tively little is clinical significant in GC. Our results showed that RGMB-AS1 is highly expressed in GC tissue samples and cell lines. Higher RGMB-AS1 expression significantly correlated with tumor size, TNM stage, and lymph node metastasis among the patients with GC. Furthermore, patients with GC in the high-RGMB-AS1 expression group demonstrated shorter overall survival than that of patients in the low-RGMB-AS1 expression group.

In terms of function, *RGMB-AS1* is reported to play oncogenic roles during cancer initiation and progression.

ample, R MB-AS1 knockdown inhibits laryngeal For squamou carcinoma cell proliferation and invasion and suppresses tumor growth of these cells in vivo.<sup>18</sup> in lung cancer, the knockdown of RGMB-AS1 restricts cell growth and metastasis, induces cell cycle arrest at the G1–G0 ansition in vitro, and slows tumor growth in vivo.<sup>19</sup> In papillary thyroid carcinoma, RGMB-AS1 knockdown attenuates cell proliferation, migration, and invasion in vitro.<sup>20</sup> In contrast, RGMB-AS1 serves as a tumor-suppressive lncRNA in hepatocellular carcinoma by inhibiting cell proliferation, migration, and invasion and facilitating apoptosis.<sup>21</sup> In the present study, we aimed to test whether a change in RGMB-AS1 expression is implicated in the malignancy of GC in vitro and in vivo. We demonstrated that RGMB-AS1 performs oncogenic functions in the malignancy of GC by inducing cell proliferation, migration, and invasion and by decreasing apoptosis in vitro. Our experiments also revealed that silencing RGMB-AS1 retarded tumor growth of GC cells in vivo.

Mechanistically, the most widely studied latent mechanism of action of lncRNAs is based on the role of a ceRNA that sponges miRNAs to alleviate the repression of their target genes.<sup>30–32</sup> Following the identification of the expression profile and functions of *RGMB-AS1* in GC, it was necessary to elucidate the mechanisms responsible for the oncogenic activities of *RGMB-AS1* in GC progression. Accordingly, we demonstrated that *RGMB-AS1*, which harbors miR-574–binding sites, can act as an effective sponge toward miR-574, thereby positively modulating HDAC4 expression. MiR-574 is underexpressed in GC, and this underexpression strongly correlates with tumor stage and differentiation status.<sup>22</sup> MiR-574 exerts tumor-suppressive actions in GC cells and participates in the control over cell growth, metastasis, epithelial– mesenchymal transition, and cisplatin resistance.<sup>22,23</sup> HDAC4, a member of the HDAC family, is overexpressed in GC, and plays multiple roles in the malignant characteristics of GC cells in vitro and in vivo.<sup>33–35</sup> Understanding the newly identified *RGMB-AS1*–miR-574–HDAC4 regulatory network can clarify the oncogenic activities of *RGMB-AS1* in GC and may point to promising therapeutic regimens for patients with GC.

#### Conclusion

In summary, the results of this study suggested that upregulation of *RGMB-AS1* in GC correlates with worse clinical outcomes. *RGMB-AS1* promotes the aggressive behavior of GC cells in vitro and in vivo, with these oncogenic activities being mediated by miR-574 sponging, thereby increasing HDAC4 expression. Our results thus offer an attractive therapeutic target in GC.

# Ethics Approval and Consent to Participate

The study protocol was approved by Ethic of The Second Hospital of Jilin Al the particiaversit pants signed an informed conse orm. Anima naintenance and experimental steps were approved by the Animal Care and Use Committee The Second Hospital of Jilin University. All exp mental teps were performed in commal rotection Law of the People's pliance with the A or experimental animals. Republic of 1-200

#### Dischaur

The authors sclare that they have no competing interests.

#### References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424. doi:10.3322/caac.21492
- Li G, Hu Y, Liu H. Current status of randomized controlled trials for laparoscopic gastric surgery for gastric cancer in China. *Asian J Endosc Surg.* 2015;8(3):263–267. doi:10.1111/ases.12198

- 4. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. *Lancet*. 2016;388(10060):2654–2664. doi:10.1016/ S0140-6736(16)30354-3
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
- Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell. 2011;145(2):178–181. doi:10.1016/j.cell.2011.03.014
- Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. *Trends Cell Biol.* 2018;28(4):287–301. doi:10.1016/j. tcb.2017.11.008
- Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. *Cell*. 2013;152(6):1298–1307. doi:10.1016/j.cell.2013.02.012
- Chi Y, Wang D, Wang J, Yu W, Yang J. Long L. coding RNA in the pathogenesis of cancers. *Cells*. 29;8(9). doi:10.190/cells8091015
- Cossu AM, Mosca L, Zappavignus, et al. Long on-coding RNAs as important biomarkers of laryng ocancer are other head and neck tumours. *Int Visiol Sci.* 201;10(14):444. doi:10.3390/ ijms20143444
- 11. Zhou R, Wu Z, Den Y, Chu H. The Jong non-coding RNA OLC8 enhances gas to cancel to interaction with IL-11. *J Clin Lab Anal*. 2019;33:e2 62.
- Deng Y. Zhao, Y. Cai J, et al. CncRNA-ANRIL promotes gastric cancel progress by enhancing NF-kB signaling. *Exp Biol Med.* 2010;244(12):953 22 doi:10.1177/1535370219860207
- Liu Y, Zhang YM, M. FB, Pan SR, Liu BZ. Long noncoding RNA HOXA11-AS promotes gastric cancer cell proliferation and invasion via SRSF1 and functions as a biomarker in gastric cancer. *World J Gastroente* 1. 2019;25(22):2763–2775. doi:10.3748/wjg.v25.i22.2763
  Y, Zhu Y, Ma Y, Qu H. IncRNA CCAT1 contributes to the growth and constitution of gastric cancer via targeting miR-219-1. *J Cell Bjochem*. 2019. doi:10.1002/jcb.26560
- 5. Z. Ig W, Feng W, Jiang Y, et al. LncRNA CTC-497E21.4 promotes the progression of gastric cancer via modulating miR-22/NET1 axis through RhoA signaling pathway. *Gastric Cancer*. 2019. doi:10.1007/ s10120-019-00998-w
- Pang W, Zhai M, Wang Y, Li Z. Long noncoding RNA SNHG16 silencing inhibits the aggressiveness of gastric cancer via upregulation of microRNA-628-3p and consequent decrease of NRP1. *Cancer Manag Res.* 2019;11:7263–7277. doi:10.2147/CMAR.S211856
- Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. *Dev Cell*. 2006;11(4):441–450. doi:10.1016/j.devcel.2006.09.009
- Xu Z, Xi K. LncRNA RGMB-AS1 promotes laryngeal squamous cell carcinoma cells progression via sponging miR-22/NLRP3 axis. *Biomed Pharmacother*. 2019;118:109222. doi:10.1016/j.biopha.2019.109222
- Li P, Zhang G, Li J, et al. Long noncoding RNA RGMB-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in lung adenocarcinoma. *PLoS One.* 2016;11(3): e0150790. doi:10.1371/journal.pone.0150790
- Zhang Z, Li SY, Zhang LB. LncRNA RGMB-AS1 is activated by E2F1 and promotes cell proliferation and invasion in papillary thyroid carcinoma. *Eur Rev Med Pharmacol Sci.* 2018;22(7):1979–1986. doi:10.26355/eurrev\_201804\_14725
- Sheng N, Li Y, Qian R, Li Y. The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellular carcinoma. *Biomed Pharmacother.* 2018;98:577–584. doi:10.1016/j.biopha.2017.12.067
- Su Y, Ni Z, Wang G, et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. *Int Immunopharmacol.* 2012;13(4):468–475. doi:10.1016/j.intimp.2012.05.016
- Wang M, Zhang R, Zhang S, Xu R, Yang Q. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells. *Gene*. 2019;700:110–119. doi:10.1016/j.gene.2019.03.043

- 24. Xuan Y, Wang Y. Long non-coding RNA SNHG3 promotes progression of gastric cancer by regulating neighboring MED18 gene methylation. *Cell Death Dis.* 2019;10(10):694. doi:10.1038/s41419-019-1940-3
- 25. Liu Y, Yin L, Chen C, Zhang X, Wang S. Long non-coding RNA GAS5 inhibits migration and invasion in gastric cancer via interacting with p53 protein. *Digest Liver Dis.* 2019. doi:10.1016/j.dld.2019.08.012
- 26. Xiao J, Lai H, Wei SH, Ye ZS, Gong FS, Chen LC. IncRNA HOTAIR promotes gastric cancer proliferation and metastasis via targeting miR-126 to active CXCR4 and RhoA signaling pathway. *Cancer Med.* 2019. doi:10.1002/cam4.1302
- 27. Cao C, Xu Y, Du K, et al. LINC01303 functions as a competing endogenous RNA to regulate EZH2 expression by sponging miR-101-3p in gastric cancer. *J Cell Mol Med.* 2019. doi:10.1111/ jcmm.14593
- 28. Da J, Liu P, Wang R, Bu L. Upregulation of the long non-coding RNA FAM83H-AS1 in gastric cancer and its clinical significance. *Pathol Res Pract*. 2019;215(10):152616. doi:10.1016/j.prp.2019.152616
- Li L, Kou J, Zhong B. Up-regulation of long non-coding RNA AWPPH inhibits proliferation and invasion of gastric cancer cells via miR-203a/ DKK2 axis. *Hum Cell*. 2019;32(4):495–503. doi:10.1007/s13577-019-00277-x

- Zhao Q, Wu C, Wang J, et al. LncRNA SNHG3 promotes hepatocellular tumorigenesis by targeting miR-326. *Tohoku J Exp Med*. 2019;249(1):43–56. doi:10.1620/tjem.249.43
- 31. Zhao H, Hu GM, Wang WL, Wang ZH, Fang Y, Liu YL. LncRNA TDRG1 functions as an oncogene in cervical cancer through sponging miR-330-5p to modulate ELK1 expression. *Eur Rev Med Pharmacol Sci.* 2019;23(17):7295–7306. doi:10.26355/eurrev\_201909\_18834
- 32. Gou L, Zou H, Li B. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1. *Cancer Biol Ther.* 2019;20:1–11.
- 33. Kang ZH, Wang CY, Zhang WL, et al. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. *PLoS One.* 2014;9(6):e98894. doi:10.1371/journal.pone.0098894
- Colarossi L, Memeo L, Colarossi C, et al. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in proceeding of the certain sector of the cert
- 35. Li Y, Wang K, Wei Y, et al. lncRNA+ dIAT regulates will biological behaviors in gastric cancer through timechanism infolving the miR-29a-3p/HDAC4 axis. *Incol Rep*, 2017;38(1):3465–3472. doi:10.3892/or.2017.6020

#### **OncoTargets and Therapy**

#### **Dove**press

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.